Evidence map›Paper›PMID 40481351›Full record

ArticleAnalytical and bioanalytical chemistry2025

LC-MS/MS-based simultaneous quantification of acylcarnitines, eicosapentaenoic acid, and docosahexaenoic acid: exploring potential biomarkers in human plasma.

Baiba Gukalova, Kristaps Krims-Davis, Eduards Sevostjanovs, Aiga Leduskrasta, Ilze Konrade, Maija Dambrova, Edgars Liepinsh

Abstract readValidation Study
In one paragraph

Article in Analytical and bioanalytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Baiba GukalovaLatvian Institute of Organic Synthesis, Aizkraukles Str 21, Riga, LV1006, Latvia. baiba.gukalova@osi.lv.
Kristaps Krims-DavisLatvian Institute of Organic Synthesis, Aizkraukles Str 21, Riga, LV1006, Latvia.
Eduards SevostjanovsLatvian Institute of Organic Synthesis, Aizkraukles Str 21, Riga, LV1006, Latvia.
Aiga LeduskrastaLatvian Institute of Organic Synthesis, Aizkraukles Str 21, Riga, LV1006, Latvia.
Ilze KonradeRiga Stradins University, Dzirciema Str 16, Riga, LV1007, Latvia.
Maija DambrovaLatvian Institute of Organic Synthesis, Aizkraukles Str 21, Riga, LV1006, Latvia.
Edgars LiepinshLatvian Institute of Organic Synthesis, Aizkraukles Str 21, Riga, LV1006, Latvia.

Funding

European Union's Horizon 2020 Framework Programme 857287State research project in the field of biomedicine, medical technologies and pharmacy VPP-EM-BIOMEDICĪNA-2022/1-0001
6 · The paper itself

Abstract

Acylcarnitines have emerged as valuable markers of the intracellular fatty acid content, mitochondrial functionality, and fatty acid metabolism. However, acylcarnitines derived from polyunsaturated fatty acids (PUFAs) have not been previously examined. To address the need for monitoring lifestyle intervention and omega-3 supplementation studies, a novel liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for the simultaneous quantification of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), eicosapentaenoyl-L-carnitine (EPAC), and docosahexaenoyl-L-carnitine (DHAC). Matrix effects were normalized using a background subtraction approach, and the analytes were extracted from blood plasma via simple protein precipitation with acetonitrile. Chromatographic separation was achieved within 5 min on a reverse-phase C18 column using a gradient mobile phase composed of ammonium acetate and acetonitrile. The limits of quantification of the method were 2 μM for EPA/DHA and 2 nM for EPAC/DHAC. The method exhibited high precision and accuracy, with coefficient of variation and bias values less than 10%. The stability tests confirmed that the analytes remained stable under various conditions, such as remaining up to 6 h at room temperature and refrigeration and undergoing three freeze-thaw cycles; however, the acylcarnitines were unstable during long-term storage. This method is simple, fast, and cost-effective; thus, it is suitable for high-throughput analysis of samples from clinical studies. A PUFA supplement study in healthy volunteers revealed a more pronounced increase in plasma EPAC and DHAC levels than in EPA and DHA levels; these results indicated that PUFA-derived acylcarnitines were potential novel and sensitive markers of PUFA intake.

Indexed as

CarnitineDocosahexaenoic AcidsEicosapentaenoic AcidTandem Mass SpectrometryBiomarkersChromatography, LiquidHumansLimit of DetectionLiquid Chromatography-Mass SpectrometryReproducibility of ResultsacylcarnitineBiomarkersCarnitineDocosahexaenoic AcidsEicosapentaenoic AcidAcylcarnitinesDocosahexaenoic acidDocosahexaenoyl-L-carnitineEicosapentaenoic acidEicosapentaenoyl-L-carnitineLC–MS/MS

Identifiers

PMID40481351
PMCPMC12283484

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.